Acorda reports Ampyra revenues

Acorda Therapeutics Inc. (NASDAQ:ACOR) reported $51.8 million in 2Q11 sales of multiple sclerosis (MS) drug Ampyra dalfampridine, up from $28 million in 2Q10. Total revenue was $65.3 million, slightly below the Street's estimate of $66 million but up 52% from $42.8 million in 2Q10. Ampyra, an oral sustained-release formulation of 4-aminopyridine, was approved in March 2010 to improve walking ability in MS patients. Acorda said it continues to expect 2011 Ampyra sales of $205-$230 million. ...